Insperity Stock Drops 15% After Reporting Q2 Earnings Miss

Insperity (NSP) reported a dismal Q2 2025, with adjusted EPS of $0.26 missing consensus by 36.6% and plummeting 69.8% year-over-year, alongside a 51.5% drop in adjusted EBITDA to $32 million and a shift to an operating loss. In response to these results, the company significantly lowered its full-year 2025 adjusted EPS guidance to $1.81-$2.51 and adjusted EBITDA guidance to $170-$205 million, both falling substantially below prior estimates and analyst consensus. This poor performance and weakened outlook, underscored by a Zacks Rank #5 (Sell), triggered a 15.3% stock decline post-earnings and contributes to its 34.9% year-to-date underperformance.

Analysis

Insperity's (NSP) second-quarter 2025 results revealed a significant deterioration in operational performance and profitability, triggering a sharp negative market reaction. Adjusted earnings of 26 cents per share represented a 69.8% year-over-year collapse and missed consensus estimates by a substantial 36.6%. While revenues grew a modest 3.3% to $1.7 billion, this was overshadowed by a severe decline in profitability, with gross profit falling 14% and the company swinging to an operating loss of $7 million from a $23 million operating income in the prior-year quarter. This was further evidenced by a 51.5% year-over-year decrease in adjusted EBITDA to $32 million. Critically, management issued a sharply weaker outlook, lowering its full-year 2025 adjusted EPS guidance to a range of $1.81-$2.51, with the midpoint of $2.16 falling well below the consensus estimate of $2.48. This guidance cut, combined with the earnings miss, resulted in a 15.3% stock price decline post-announcement, compounding its year-to-date underperformance of -34.9% against both its industry and the S&P 500.

Key Decisions for Investors

• Given the severe earnings miss, collapsing profitability, and significantly lowered full-year guidance, investors should exercise extreme caution, as the current operational challenges appear deep-seated.
• The stock's recovery is contingent on a turnaround in margins and profitability; therefore, monitor gross margin trends and operating income figures in subsequent quarters as key performance indicators.
• Management's credibility now rests on achieving the new, lower guidance, making the next earnings report a critical catalyst; any failure to meet these reduced expectations could lead to further downside.
• With the stock's material underperformance against its industry and the broader market, coupled with a Zacks #5 (Sell) rating, reallocating capital to stronger fundamental stories within the sector may be a prudent strategy until a clear turnaround is visible.